TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
TRINITY BIOTECH PLC
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 30, 2026
$8.19+0.16 (+1.99%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Trinity Biotech statistics
Financials through Dec 31, 2024, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison
Valuation
| Measure | Trinity Biotech | Industry median |
|---|---|---|
| Market Cap | $153.24M | $164.85M |
| Enterprise Value | $148.28M | $87.06M |
| PS Ratio | 2.49 | 3.60 |
Enterprise value
| Measure | Trinity Biotech | Industry median |
|---|---|---|
| EV / Sales | 2.41 | 2.43 |
Income (trailing twelve months)
| Measure | Trinity Biotech | Industry median |
|---|---|---|
| Revenue | $61.56M | $57.94M |
| Gross Profit | $21.44M | $90.47M |
| Operating Income | -$21.17M | -$21.44M |
| Pretax Income | -$30.73M | -$14.45M |
| Net Income | -$31.79M | -$22.46M |
| EBITDA | -$20.96M | -$16.91M |
Margins
| Measure | Trinity Biotech | Industry median |
|---|---|---|
| Gross Margin | 34.8% | 52.3% |
| Operating Margin | -34.4% | -44.5% |
| Pretax Margin | -49.9% | -13.0% |
| Profit Margin | -51.6% | -39.2% |
| EBITDA Margin | -34.1% | -31.3% |
| FCF Margin | -7.47% | -8.85% |
Returns
| Measure | Trinity Biotech | Industry median |
|---|---|---|
| Return on Assets (ROA) | -30.8% | -41.0% |
| Return on Capital Employed (ROCE) | -29.7% | -37.8% |
Growth
| Measure | Trinity Biotech | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 8.31% | 6.01% |
| Revenue Growth (3Y CAGR) | -8.80% | 2.25% |
| Revenue Growth (5Y CAGR) | -7.41% | 6.42% |
Balance sheet
| Measure | Trinity Biotech | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $5.17M | $62.42M |
| Total Debt | $210.00K | $120.13M |
| Net Cash (Debt) | $4.96M | $15.68M |
| Net Cash Per Share | $0.01 | $0.66 |
| Working Capital | $9.03M | $75.77M |
Financial position
| Measure | Trinity Biotech | Industry median |
|---|---|---|
| Current Ratio | 1.28 | 3.30 |
| Quick Ratio | 0.66 | 2.39 |
| Interest Coverage | -2.21 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Trinity Biotech | Industry median |
|---|---|---|
| Operating Cash Flow | -$4.19M | -$12.35M |
| Capital Expenditures | -$405.00K | -$1.06M |
| Free Cash Flow | -$4.60M | -$20.28M |
| FCF Per Share | -$0.01 | -$0.42 |
Efficiency
| Measure | Trinity Biotech | Industry median |
|---|---|---|
| Asset Turnover | 0.60 | 0.38 |
| Inventory Turnover | 2.07 | 2.67 |
| Revenue Per Employee | $214.48K | $398.96K |
| Profits Per Employee | -$110.76K | -$703.34K |
| Employee Count | 287 | 74 |
Dividends and yields
| Measure | Trinity Biotech | Industry median |
|---|---|---|
| Earnings Yield | -20.7% | -22.7% |
| FCF Yield | -3.00% | -9.07% |
| Buyback Yield | -4.82% | -0.73% |
| Shareholder Yield | -4.82% | 0.00% |
Shares
| Measure | Trinity Biotech | Industry median |
|---|---|---|
| Shares Outstanding | 374,207,000 | 58,179,650 |
| Shares Change (YoY) | 134.6% | 11.1% |
Taxes
| Measure | Trinity Biotech | Industry median |
|---|---|---|
| Income Tax | $486.00K | $91.50K |
Scores
| Measure | Trinity Biotech | Industry median |
|---|---|---|
| Altman Z-Score | -0.38 | -0.24 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -3.42 | -2.62 |
Calculated by StockData from Trinity Biotech's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.